Pediatrix Medical Group (NYSE:MD) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Pediatrix Medical Group (NYSE:MD) announced its quarterly earnings data on Tuesday. The company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.04, FiscalAI reports. Pediatrix Medical Group had a net margin of 9.02% and a return on equity of 19.94%. During the same period last year, the company posted $0.53 earnings per share. The business’s revenue for the quarter was up 4.1% compared to the same quarter last year.

Here are the key takeaways from Pediatrix Medical Group’s conference call:

• Q2 adjusted EBITDA was $76 million, and management reaffirmed its 2026 adjusted EBITDA outlook of $280 million–$300 million.
• Consolidated revenue increased 4%, with same-unit revenue up 2% as stronger RCM collections, favorable payer mix, and higher patient acuity more than offset lower volumes.
• Same-unit patient service volumes declined 2%, including a 3% decrease in NICU days; management expects full-year volume to be flat to slightly down and said RCM collection benefits will begin to fade in the second half.
• The company repurchased nearly 2 million shares during the quarter, bringing total buybacks since August 2025 to 7 million shares and reducing shares outstanding to 81 million.
• Pediatrix is pursuing growth through tele-hybrid services, obstetric hospitalist programs, acquisitions, and potential joint ventures in women’s and children’s healthcare, while emphasizing disciplined financial and operating returns.

Pediatrix Medical Group Price Performance

Shares of MD traded down $1.26 during midday trading on Tuesday, hitting $24.99. 658,912 shares of the company traded hands, compared to its average volume of 795,049. The stock has a market cap of $2.05 billion, a price-to-earnings ratio of 12.13 and a beta of 0.66. The firm has a 50 day moving average of $24.70 and a 200-day moving average of $22.52. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.33 and a current ratio of 1.33. Pediatrix Medical Group has a 52 week low of $12.77 and a 52 week high of $27.94.

Insider Activity

In related news, Director Shirley A. Weis sold 36,028 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $23.75, for a total value of $855,665.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 1.80% of the company’s stock.

Institutional Trading of Pediatrix Medical Group

Several hedge funds have recently modified their holdings of MD. Kestra Advisory Services LLC bought a new position in Pediatrix Medical Group during the 4th quarter valued at about $140,000. Financiere des Professionnels Fonds d investissement inc. purchased a new position in shares of Pediatrix Medical Group during the fourth quarter valued at approximately $215,000. New Vernon Capital Holdings II LLC bought a new position in shares of Pediatrix Medical Group during the third quarter valued at approximately $196,000. Boothbay Fund Management LLC bought a new position in Pediatrix Medical Group in the 3rd quarter valued at $180,000. Finally, Envestnet Asset Management Inc. purchased a new stake in Pediatrix Medical Group in the third quarter worth $213,000. 97.71% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. UBS Group lifted their price target on shares of Pediatrix Medical Group from $22.00 to $25.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th. Mizuho set a $24.00 price objective on shares of Pediatrix Medical Group in a research report on Friday, May 8th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Wednesday, June 24th. Jefferies Financial Group reiterated a “buy” rating and issued a $27.00 price target on shares of Pediatrix Medical Group in a research note on Monday, April 20th. Finally, Truist Financial boosted their price objective on Pediatrix Medical Group from $23.00 to $28.00 and gave the company a “hold” rating in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, Pediatrix Medical Group has a consensus rating of “Hold” and an average price target of $23.33.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.